Hearing Date: Thursday February 02, 2017
Committee On: Health and Human Services
Introducer: Hilkemann
One Liner: Change provisions relating to infant health screenings

Roll Call Vote - Final Committee Action:
Advanced to General File with amendment(s)

Vote Results:
Aye: 6 Senators Crawford, Erdman, Howard, Kolterman, Linehan, Williams
Nay: 1 Senator Riepe
Absent:
Present Not Voting:

Verbal Testimony:
Proponents: Representing:
Senator Robert Hilkemann Introducer
Dr. William Rizzo Self
Meghan Korth Self
Jeff Swanson Self
Shannon Butalla Self
Ashlee Springer Self

Opponents: Representing:

Neutral: Representing:

Summary of purpose and/or changes:
LB 91 updates the Newborn Screening Program by adding congenital to primary hypothyroidism and adds definition of "pharmaceutically manufactured foods". LB 91 also changes the fee set by the Department of Health and Human Services for the administration of the Newborn Screening Program to no more than $20.00.

SECTION BY SECTION:

Section (1): Amends Section 71-519 to add congenital to primary hypothyroidism. Replace metabolic with congenital infant or childhood-onset diseases to list of mandated infant screenings. Strikes metabolic from disease testing the department will have authority over the use. Strike lamination as option to store blood specimen. Adds inherited or congenital infant or childhood-onset diseases to dietary and therapeautic management to be responsibility of parent.

Section (2): Amends Section 71-520 to add inherited or congenital infant or childhood-onset diseases to mandate on Department for programs regarding food supplements and treatment. Defines "pharmaceutically manufactured foods."

Section (3): Amends Section 71-523 to strike metabolic diseases and replaces with screened diseases regarding educational and resource serviced mandated from the Department. Strikes ten dollars and replaces with twenty dollars for fee allowed to be collected by the Department.
Section (4): Repeals Sections 71-519, 71-520, and 71-523.

Explanation of amendments:
AM331 amends LB401 into LB91, by adding X-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidosis type I (MPS-1) and Pompe disease to the list of mandatory infant screenings.

______________________________
Merv Riepe, Chairperson